
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Immunol. , 21 September 2023
Sec. Molecular Innate Immunity
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1294153
This article is a correction to:
Complement Activation via the Lectin and Alternative Pathway in Patients With Severe COVID-19
A Corrigendum on
Complement activation via the lectin and alternative pathway in patients with severe COVID-19
by Niederreiter J, Eck C, Ries T, Hartmann A, Märkl B, Büttner-Herold M, Amann K and Daniel C (2022) Front. Immunol. 13:835156. doi: 10.3389/fimmu.2022.835156
In the published article, information in the Acknowledgments was mistakenly not included in the publication. A correction has been made to Acknowledgments:
The present work was performed in (partial) fulfillment of the requirements for obtaining the degree ‘Dr. med.’ from the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) for JN. The technical assistance of Stefan Söllner, Sina Dassler, Carolin Hamann, Iris Scheitacker and Miriam Reutelshöfer is gratefully acknowledged. The authors are thankful to Lukas Borcherding for compiling the cases from the Augsburg Autopsy Series.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: complement deposition, COVID-19, kidney, lung, autopsy, lectin pathway
Citation: Niederreiter J, Eck C, Ries T, Hartmann A, Märkl B, Buettner-Herold M, Amann K and Daniel C (2023) Corrigendum: Complement activation via the lectin and alternative pathway in patients with severe COVID-19. Front. Immunol. 14:1294153. doi: 10.3389/fimmu.2023.1294153
Received: 14 September 2023; Accepted: 15 September 2023;
Published: 21 September 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Niederreiter, Eck, Ries, Hartmann, Märkl, Buettner-Herold, Amann and Daniel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Christoph Daniel, Q2hyaXN0b3BoLkRhbmllbEB1ay1lcmxhbmdlbi5kZQ==
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.